Group 1 - The article discusses the importance of enabling Javascript and cookies in browsers to prevent access issues [1] - It highlights that users with ad-blockers may face restrictions when trying to access content [1]

Group 1 - The core viewpoint of the article highlights that Innovent Biologics (01801) has achieved significant revenue growth, with total product revenue reaching approximately RMB 11.9 billion in 2025, marking a 45% year-on-year increase and surpassing the RMB 10 billion milestone for the first time [1] - In Q4 2025, the company reported total product revenue of approximately RMB 3.3 billion, reflecting over 60% year-on-year growth, indicating a strong growth momentum [1] - The announcement notes that in Q4 2025, due to six new drugs being included in the 2026 National Medical Insurance Directory, Innovent Biologics accounted for a one-time inventory adjustment based on original pricing for products distributed to channels [1] Group 2 - Haitong International expressed that despite the one-time inventory adjustment impact, the company's Q4 performance met their expectations, and they remain optimistic about the accelerated market penetration of the six new drugs following their inclusion in the insurance directory [1]

Core Viewpoint - The company achieved a total product revenue of approximately RMB 11.9 billion in 2025, marking a 45% year-on-year increase and surpassing the RMB 10 billion milestone for the first time [1] Group 1: Financial Performance - In the fourth quarter of 2025, the company reported total product revenue of approximately RMB 3.3 billion, reflecting a year-on-year growth of over 60% [1] - The strong growth momentum is expected to continue, driven by the inclusion of six new drugs in the 2026 National Medical Insurance Directory [1] Group 2: Market Impact - The company accounted for a one-time inventory adjustment due to the distribution of products at original prices, following the inclusion of new drugs in the insurance directory [1] - Haitong International expressed that the fourth-quarter performance met their expectations, and they are optimistic about the accelerated market penetration of the six new drugs post-inclusion in the insurance directory [1]

卫光生物表示，本项目的建设实施，是公司立足现有核心优势，从血液制品领域向生物医药前沿赛道延 伸拓展的重要战略举措，有利于公司进一步完善生物医药领域战略布局，培育新的业务增长点，增强公 司差异化竞争优势，是公司实现战略升级、推动高质量发展的重要抓手。 北京商报讯（记者 丁宁）2月5日，卫光生物（002880）盘中股价大涨，一度涨逾8%。截至北京商报记 者发稿，卫光生物报33.31元/股，涨幅为8.43%。 消息面上，卫光生物发布公告称，公司拟与深圳市深业生物医药产业发展有限公司、深圳细胞谷生物医 药有限公司及深圳赛桥生物创新技术有限公司共同出资设立深圳市羲和生命科技有限责任公司（暂定 名，以工商部门最终登记结果为准），建设深圳市细胞与基因治疗市场化公共服务平台。新设公司初始 注册资本为1亿元，卫光生物认缴4000万元，占其股权比例为40%。 ...

Core Viewpoint - Aimeike's stock price has increased by 5.09% on February 5, reaching 155.87 CNY per share, with a total market capitalization of 47.165 billion CNY, marking a cumulative increase of 6.15% over three consecutive days [1] Group 1: Company Overview - Aimeike Technology Development Co., Ltd. is located in Chaoyang District, Beijing, and was established on June 9, 2004, with its IPO on September 28, 2020 [1] - The company's main business involves the research, production, and sales of biomedical soft tissue repair materials, with revenue composition as follows: 57.27% from solution injection products, 37.97% from gel injection products, 3.01% from others, 1.50% from freeze-dried powder injection products, and 0.26% from facial implant threads [1] Group 2: Shareholder Insights - Huatai-PB Fund's Huatai-PB CSI 300 ETF (510300) is among Aimeike's top ten circulating shareholders, having reduced its holdings by 85,400 shares to 2.6773 million shares, representing 1.28% of circulating shares [2] - The ETF has generated a floating profit of approximately 20.2138 million CNY today and 22.9982 million CNY during the three-day increase [2] - The Huatai-PB CSI 300 ETF was established on May 4, 2012, with a current scale of 422.258 billion CNY, yielding 1.56% this year and 26.25% over the past year [2] Group 3: Fund Performance - The Huatai-PB Health ETF (516790) has also heavily invested in Aimeike, having reduced its holdings by 5,700 shares to 18,900 shares, accounting for 2.73% of the fund's net value [3] - The ETF has achieved a floating profit of approximately 142,500 CNY today and 162,200 CNY during the three-day increase [3] - The Huatai-PB Health ETF was established on August 12, 2021, with a current scale of 98.1452 million CNY, yielding 6.43% this year and 12.82% over the past year [3]

Core Viewpoint - The article discusses a large-scale healthcare fraud case involving hemophilia patients, pharmaceutical representatives, and private hospitals in Zhejiang, China, highlighting the complexities of healthcare reimbursement policies and the ethical dilemmas faced by patients and medical professionals [1][2][20]. Group 1: Fraud Scheme Details - The fraud scheme involved pharmaceutical representatives, private hospitals, and dispensing companies colluding to induce patients to falsely claim medical expenses for hemophilia medications, leading to significant financial losses for the healthcare system [1][13][15]. - Patients were offered incentives, such as a 4% rebate on medication purchases, which encouraged them to participate in the fraudulent activities [8][9][12]. - The scheme exploited the reimbursement policies that limited adult hemophilia patients to medication use only during bleeding episodes, creating a loophole that allowed for excessive and unnecessary prescriptions [2][20][21]. Group 2: Patient Experiences and Impacts - Hemophilia patients, particularly those with severe conditions, relied on medications like recombinant factor VIII to manage their health, often leading to a high frequency of prescriptions [5][9][34]. - The fraudulent practices have resulted in patients facing difficulties in obtaining necessary medications, as hospitals have become more cautious in prescribing due to the legal implications of the fraud cases [33][34]. - The article highlights the emotional and physical toll on patients, who now struggle to access their medications and face stigma associated with the fraud allegations [33][34]. Group 3: Regulatory and Policy Implications - The case has drawn attention to the discrepancies between healthcare policies and the best treatment practices for hemophilia, particularly the need for preventive treatment versus the current reimbursement limitations [2][31]. - Experts argue that the existing healthcare reimbursement policies do not adequately address the needs of hemophilia patients, leading to a conflict between patient care and regulatory compliance [30][31]. - The fraud case has prompted stricter enforcement of healthcare policies, impacting the availability of medications for patients and raising concerns about the future of treatment for hemophilia in the region [33][34].

Core Viewpoint - Amgen reported strong performance in 2025 with a 10% year-over-year growth in revenue and non-GAAP earnings per share, driven by its cholesterol-lowering drug, Leqvio, and a robust pipeline of innovative therapies [5][10][12]. Financial Performance - Total revenue for 2025 reached $36.751 billion, a 10% increase from $33.424 billion in 2024 [12]. - Product sales also grew by 10% to $35.148 billion, accounting for over 90% of total revenue [12]. - Non-GAAP net income rose to $11.837 billion, reflecting a 10% increase, with non-GAAP EPS reaching $21.84, up 10% from the previous year [12][13]. - Free cash flow for the year was $8.1 billion, supporting R&D investments and shareholder returns, with dividends per share increasing by 6% to $2.38 [13]. R&D Pipeline - Amgen invested $7 billion in R&D in 2025, focusing on four therapeutic areas: general medicine, rare diseases, inflammation, and oncology [16]. - The pipeline includes significant programs such as MariTide for chronic weight management and Repatha for cardiovascular outcomes, with multiple Phase 3 studies ongoing [24][27]. - MariTide has shown promising Phase 2 results, maintaining weight loss in patients and demonstrating safety [24][26]. Product Performance - In general medicine, Repatha achieved $3.016 billion in sales, a 36% increase, while EVENITY grew by 34% to $2.1 billion [66]. - Rare disease products UPLIZNA and TAVNEOS saw explosive growth, with UPLIZNA's sales increasing by 73% to $655 million [68]. - In the inflammation sector, TEZSPIRE's sales grew by 52% to $1.478 billion, despite declines in other products due to biosimilar competition [71]. Market Outlook - For 2026, Amgen set a revenue guidance of $37.0 billion to $38.4 billion and non-GAAP EPS of $21.60 to $23.00, reflecting confidence in core product growth and pipeline advancements [76][77]. - Key growth drivers include the clinical advancement of MariTide and Olpasiran, expansion of existing products like Repatha and TEZSPIRE, and continued growth in the rare disease segment [77]. Strategic Positioning - Amgen's 2025 performance underscores the importance of innovation and a strong pipeline in the competitive biopharmaceutical market [78]. - The company maintains a dual focus on deepening its core therapeutic areas while strategically expanding its pipeline through acquisitions and collaborations [78].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 自願公告 與麥科奧特簽訂協議 以於大中華區及其他亞洲市場商業化MT1013 本 公 告 由 雲 頂 新 耀 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）自 願 作 出。 本公司董事會（「董事會」）欣然宣佈，於2026年2月4日，本公司的間接全資附屬公 司雲頂新耀醫藥科技有限公司（「該附屬公司」）與陝西麥科奧特醫藥科技股份有限 公司（「麥科奧特」）訂立協議（「該協議」），據此麥科奧特已不可撤銷授予該附屬公 司於中國及亞太區（ 日本除外 ）的MT1013的獨家商業化授權，MT1013為全球首創 的雙 靶點受 體激動 劑多肽 ，可同 時靶向 鈣敏感 受體(Ca SR)及 成骨生 長肽(OGP) 受 體，開發主要用於治療繼發 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：000403 证券简称：派林生物 公告编号：2026-002 药物名称：人凝血因子IX 剂型：注射剂 规格：500IU/瓶，复溶后10ml 申请事项：境内生产药品注册上市许可 申请人：广东双林生物制药有限公司 派斯双林生物制药股份有限公司 关于全资子公司获得药品注册上市许可受理通知书的公告 本公司及董事会全体成员保证信息披露的内容的真实、准确和完整，没有虚假记载、误导性陈述或者重 大遗漏。 近日，派斯双林生物制药股份有限公司（以下简称"公司"）之全资子公司广东双林生物制药有限公司 （以下简称"广东双林"）收到国家药品监督管理局核准签发的人凝血因子IX药品注册上市许可《受理通 知书》（受理号：XCSS2600002），现将有关情况公告如下： 一、药品基本情况 五、风险提示 公司已获得人凝血因子IX药品注册上市许可《受理通知书》，具体审批完成时间尚不确定，公司将按 照国家有关规定，积极推进上述研发项目，将根据后续进展情况及时履行信息披露义务，敬请广大投资 者注意投资风险。 审批结论：根据《中华人民共和国行政许可法》第三十二条的规定，经审查，决定予以受理。 ...

Trading Information Summary - On February 4, 2026, Jiet Bio (688026) closed at 18.41 yuan, up 0.99%, with a turnover rate of 1.33% and a trading volume of 18,700 shares, amounting to a total transaction value of 34.1688 million yuan [1] - The net inflow of main funds was 2.7775 million yuan, accounting for 8.13% of the total transaction value [2] - Retail investors experienced a net outflow of 2.9683 million yuan, representing 8.69% of the total transaction value [1] Company Announcement Summary - Jiet Bio is involved in a legal dispute with Shenzhen Hesheng Medical Technology Co., Ltd. regarding nine "Mold Procurement Contracts," with a total amount in dispute of 10,340,829.00 yuan [1] - The court ruled to terminate the contracts and rejected all claims from both parties, including Jiet Bio's other litigation requests and Hesheng Medical's counterclaims [2] - Jiet Bio has fully provided for bad debts related to the advance payment made to Hesheng Medical and plans to appeal the court's decision, with the impact on current and future profits yet to be determined [1]